Total Payments
$140,142
2023 Payments
$4,061
Companies
5
Transactions
10
Medicare Patients
163
Medicare Billing
$34,904

Payment Breakdown by Category

Other$135,334 (96.6%)
Consulting$2,855 (2.0%)
Research$1,821 (1.3%)
Food & Beverage$131.44 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Grant $133,334 2 95.1%
Consulting Fee $2,855 2 2.0%
Honoraria $2,000 1 1.4%
Unspecified $1,821 3 1.3%
Food and Beverage $131.44 2 0.1%

Payments by Type

General
$138,320
7 transactions
Research
$1,821
3 transactions

Top Paying Companies

Company Total Records Latest Year
Genentech, Inc. $133,334 2 $0 (2019)
AstraZeneca Pharmaceuticals LP $2,061 2 $0 (2023)
ChromaCode, Inc $2,000 1 $0 (2023)
Novartis Pharmaceuticals Corporation $1,821 3 $0 (2020)
AstraZeneca UK Limited $925.00 2 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2023 $4,061 3 AstraZeneca Pharmaceuticals LP ($2,061)
2020 $1,678 2 Novartis Pharmaceuticals Corporation ($1,678)
2019 $66,667 1 Genentech, Inc. ($66,667)
2018 $67,735 4 Genentech, Inc. ($66,667)

All Payment Transactions

10 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
06/15/2023 ChromaCode, Inc Honoraria Cash or cash equivalent $2,000.00 General
05/14/2023 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $2,055.00 General
04/28/2023 AstraZeneca Pharmaceuticals LP Food and Beverage In-kind items and services $6.44 General
01/30/2020 Novartis Pharmaceuticals Corporation LGK974 (Drug) In-kind items and services $178.00 Research
Study: RESEARCH RELATED PUBLICATIONS SUPPORT
01/23/2020 Novartis Pharmaceuticals Corporation LGK974 (Drug) In-kind items and services $1,500.00 Research
Study: RESEARCH RELATED PUBLICATIONS SUPPORT
07/01/2019 Genentech, Inc. Grant Cash or cash equivalent $66,667.00 General
07/10/2018 AstraZeneca UK Limited IMFINZI (Drug) Consulting Fee Cash or cash equivalent $800.00 General
Category: Oncology
07/03/2018 Genentech, Inc. Grant Cash or cash equivalent $66,667.00 General
04/15/2018 AstraZeneca UK Limited Food and Beverage In-kind items and services $125.00 General
01/23/2018 Novartis Pharmaceuticals Corporation WNT974 (Drug) In-kind items and services $143.25 Research
Study: RESEARCH RELATED PUBLICATION SUPPORT

Research Studies & Clinical Trials

Study Name Company Amount Records
RESEARCH RELATED PUBLICATIONS SUPPORT Novartis Pharmaceuticals Corporation $1,678 2
RESEARCH RELATED PUBLICATION SUPPORT Novartis Pharmaceuticals Corporation $143.25 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 4 54 82 $47,306 $8,971
2022 1 18 48 $34,205 $5,605
2021 3 51 99 $57,485 $11,828
2020 2 40 90 $41,094 $8,502
Total Patients
163
Total Services
319
Medicare Billing
$34,904
Procedure Codes
10

All Medicare Procedures & Services

10 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 16 32 $23,416 $3,799 16.2%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 14 22 $8,778 $2,235 25.5%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 12 12 $10,664 $1,856 17.4%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 12 16 $4,448 $1,081 24.3%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 18 48 $34,205 $5,605 16.4%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 28 66 $40,252 $8,255 20.5%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 12 22 $8,778 $1,972 22.5%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 11 11 $8,455 $1,600 18.9%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 26 66 $32,766 $6,297 19.2%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 14 24 $8,328 $2,204 26.5%

About Dr. Marios Giannakis, MD

Dr. Marios Giannakis, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2009. The National Provider Identifier (NPI) number assigned to this provider is 1417185729.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marios Giannakis, MD has received a total of $140,142 in payments from pharmaceutical and medical device companies, with $4,061 received in 2023. These payments were reported across 10 transactions from 5 companies. The most common payment nature is "Grant" ($133,334).

As a Medicare-enrolled provider, Giannakis has provided services to 163 Medicare beneficiaries, totaling 319 services with total Medicare billing of $34,904. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.

Practice Information

Products in Payments

  • LGK974 (Drug) $1,678
  • IMFINZI (Drug) $800.00
  • WNT974 (Drug) $143.25

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Boston